At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,468 enrolled
Drug / intervention
AMG 162 +1 moredrug
Likely dose
AMG 162 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating AMG 162 and Placebo for Prostate Cancer. Completed, enrolled 1,468 participants.
Detailed Summary
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2004
First PostedAug 2004
Primary CompletionMay 2008
Study CompletionMay 2010
TodayJul 2026
First PostedAug 11, 2004
Enrollment StartAug 1, 2004
Primary CompletionMay 16, 2008
Study CompletionMay 11, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 21.9 years ago
Interventions
AMG 162drug
60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Placebodrug
60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30